Severe hand, foot, and mouth disease associated with Coxsackievirus A6--Alabama, Connecticut, California, and Nevada, November 2011-February 2012.
From November 7, 2011, to February 29, 2012, CDC received reports of 63 persons with signs and symptoms of HFMD or with fever and atypical rash in Alabama (38 cases), California (seven), Connecticut (one), and Nevada (17). HFMD is not a reportable disease in the United States; the cases were identified as unusual by health-care providers or by a department of health that contacted CDC for diagnostic assistance. Clinical specimens were collected from patients in 34 of the 63 cases. Coxsackievirus A6 (CVA6) was detected in 25 (74%) of those 34 patients by reverse transcriptase-polymerase chain reaction and partial sequencing of the VP1 gene at CDC or at the California Department of Public Health. No enteroviruses were detected in the other nine patients.
Of the 63 patients, 40 (63%) were aged <2 years, and 15 (24%) were adults aged [greater than or equal to] 18 years; 44 (70%) of the patients had exposure to a child care facility or school, and eight (53%) of the 15 adults had contact with children in child care where cases of HFMD were reported, or provided medical care or were related to a child with HFMD. Rash and fever were more severe, and hospitalization was more common than with typical HFMD. Signs of HFMD included fever (48 patients [76%]); rash on the hands or feet, or in the mouth (42 [67%]); and rash on the arms or legs (29 [46%]), face (26 [41%]), buttocks (22 [35%]), and trunk (12 [19%]). Of 46 patients with rash variables reported, the rash typically was maculopapular; vesicles were reported in 32 (70%) patients and scabs in 30 (65%) patients. Shedding of nails occurred after initial infection in two (4%) patients. Of the 63 patients, 51 (81%) sought care from a clinician, and 12 (19%) were hospitalized. Reasons for hospitalization varied and included dehydration and/or severe pain. No deaths were reported.
The age ranges of patients, severity of illness, seasonality of disease, and identification of CVA6 in these cases were unusual for HFMD in the United States. CVA6 has been associated with more severe and extensive rash than HFMD caused by other enteroviruses (1). Since 2008, international outbreaks of CVA6 HFMD in children and adults have been described (1-4), but no outbreaks had been reported in the United States previously. Although all 25 of the CVA6 strains identified in the U.S. cases were genetically closely related (based on partial VP1 gene sequences) to CVA6 strains identified in recent international outbreaks, no epidemiologic evidence (e.g., travel history) has directly linked any of the U.S. cases to importation.
HFMD is spread from person to person by contact with saliva, respiratory secretions, fluid in vesicles, and feces. Transmission of HFMD can be reduced by maintaining good hygiene, including handwashing and disinfection of surfaces in child care settings (5). CDC continues to receive reports of CVA6-associated HFMD. Persons who suspect a severe case of HFMD should contact their health-care provider. Local or state health departments may contact CDC for assistance with enterovirus laboratory diagnosis.
(1.) Wei SH, Huang YP, Liu MC, et al. An outbreak of coxsackievirus A6 hand, foot, and mouth disease associated with onychomadesis in Taiwan, 2010. BMC Infect Dis 2011;11:346.
(2.) Blomqvist S, Klemola P, Kaijalainen S, et al. Co-circulation of coxsackievirus A6 and A10 in hand, foot and mouth disease outbreak in Finland. J Clin Virol 2010;48:49-54.
(3.) Fujimoto T, Iizuka S, Enomoto M, et al. Hand, foot and mouth disease caused by coxsackievirus A6, Japan, 2011. Emerg Infect Dis 2012; 18:337-9.
(4.) Wu Y, Yeo A, Phoon MC, et al. The largest outbreak of hand, foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. Int J Infect Dis 2010;14:e1076-81.
(5.) Ruan F, Yang T, Ma H, et al. Risk factors for hand, foot, and mouth disease and herpangina and the preventative effect of hand-washing. Pediatrics 2011;127:e898-904.
Mary G. McIntyre, MD, Kelly M. Stevens, MS, Sherri Davidson, MPH, Tina Pippin, Dagny Magill, MPH, Alabama Dept of Health. Julie A. Kulhanjian, MD, Children's Hospital and Research Center, Oakland; Daniel Kelly, MD, Pacific Pediatrics Medical Group, San Francisco; Tara L. Greenhow, MD, Kaiser Permanente, San Francisco; Maria L. Salas, MPH, Shigeo Yagi, PhD, Tasha Padilla, Ricardo Berumen, Carol Glaser, MD, California Dept of Public Health. Marie Louise Landry, MD, Jason Lott, MD, Yale New Haven Hospital, New Haven, Connecticut. Lei Chen, PhD, Susanne Paulson, Melissa Peek, Kathleen Hanley, Randall Todd, DrPH, Joseph Iser, MD, DrPH, Washoe County Health District, Reno, Nevada. Dianna M. Blau, DVM, PhD, Div of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases; Shannon Rogers, MS, Allan Nix, Steve Oberste, PhD, Lauren J. Stockman, MPH, Eileen Schneider, MD, Div of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC. Corresponding contributor: Lauren J. Stockman, firstname.lastname@example.org, 404-639-2553.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Notes from the Field|
|Author:||McIntyre, Mary G.; Stevens, Kelly M.; Davidson, Sherri; Pippin, Tina; Magill, Dagny; Kulhanjian, Jul|
|Publication:||Morbidity and Mortality Weekly Report|
|Date:||Mar 30, 2012|
|Previous Article:||FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella.|